Navigation Links
Clinical Trials Move to Emerging Regions, Heighten Need for Local Risk Consulting: Aon Global Risk Map
Date:9/17/2009

CHICAGO, Sept. 17 /PRNewswire-FirstCall/ -- Aon Corporation (NYSE: AOC), the leading global provider of risk management services, insurance and reinsurance brokerage, and human capital consulting, today issued the findings of its 2009 Clinical Trials Risk Map to address the constantly changing environment in which biotechnology, pharmaceutical and medical device companies conduct business around the world.

(Logo: http://www.newscom.com/cgi-bin/prnh/20041215/CGW049LOGO)

The likelihood that a clinical trial may be negatively impacted is on the rise in relation to the increasing scrutiny and compliance regulations associated with the shift in recent years toward moving clinical trials from the U.S. and Western Europe to emerging regions such as Eastern Europe, Latin America and Asia.

While the decision to conduct clinical trials abroad varies based upon each life sciences company's unique needs, a complex insurance regulatory environment is all but guaranteed across the industry. An additional challenge identified by the 2009 Clinical Trials Risk Map is the increasing number of countries that now require admitted insurance coverage, or coverage that is purchased from an insurance company licensed within the country where the trial is being conducted.

"In the past, a certificate of insurance could be issued in the U.S., stating that the policy in place would address any liabilities associated with a clinical trial," stated James Walters, managing director of Aon's Life Sciences practice and author of the 2009 Clinical Trials Risk Map. "Today, life sciences firms must often secure local country coverage, which requires the understanding of legal requirements in each jurisdiction. Without the proper counsel on the ground, the risk of error can be costly and ultimately result in a delayed or cancelled clinical trial."

Aon's 2009 Clinical Trials Risk Map assigns symbols to countries around the world to identify:

  • Compulsory clinical trials insurance requirements - government-mandated
  • Extended reporting or life-of-trial requirements - government-mandated
  • Compulsory limit of liability - government-regulated
  • High compulsory limit of liability - government-regulated
  • Deductibles permitted by law
  • Broker-issued insurance certificate permitted by regulatory authorities
  • Admitted insurance requirements by local country
  • Countries where Aon has a physical presence in one or multiple cities

Often fraught with intricacies related to local language regulations, levels of coverage and the specific contractual language required, clinical trials insurance demands the focused attention of a risk management partner intimately familiar with navigating each country's requirements to secure the proper admitted clinical trials insurance coverage.

About the 2009 Aon Clinical Trials Risk Map

The annual Clinical Trials Risk Map, produced by Aon's Life Sciences practice, provides an overview of clinical trial insurance complexities encountered by life sciences companies when conducting clinical trials around the globe. The map is based on the practice's expertise in placing coverage and mitigating risk for these firms in over 70 countries throughout the world. The global network of Aon's life sciences experts is positioned to assist life sciences companies to efficiently and effectively secure international coverage for their clinical trials in adherence to the regulatory environments of individual countries.

To register for a copy of Aon's 2009 Clinical Trials Risk Map, visit http://www.aon.com/clinicaltrialsmap.

Follow Aon on Twitter: http://www.twitter.com/aoncorp

Sign up for News Alerts: http://aon.mediaroom.com/index.php?s=58

About Aon

Aon Corporation (NYSE: AOC) is the leading global provider of risk management services, insurance and reinsurance brokerage, and human capital consulting. Through its more than 37,000 colleagues worldwide, Aon readily delivers distinctive client value via innovative and effective risk management and workforce productivity solutions. Aon's industry-leading global resources and technical expertise are delivered locally through more than 500 offices in more than 120 countries. Named the world's best broker by Euromoney magazine's 2008 and 2009 Insurance Survey, Aon also ranked highest on Business Insurance's listing of the world's largest insurance brokers based on commercial retail, wholesale, reinsurance and personal lines brokerage revenues in 2008. A.M. Best deemed Aon the number one insurance broker based on brokerage revenues in 2007 and 2008, and Aon was voted best insurance intermediary, best reinsurance intermediary and best employee benefits consulting firm in 2007 and 2008 by the readers of Business Insurance. For more information on Aon, log onto http://www.aon.com.

    Media Contact
    Kelly Drinkwine               Tiffany Greco
    312.381.2684                  312.755.3549
    kelly_drinkwine@aon.com       tiffany.greco@kemperlesnik.com


'/>"/>
SOURCE Aon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. New Assay Detects 100 Percent of Stage I, II and III Colon Cancers in Pre-Clinical Trials
2. CEL-SCI to Commence First Clinical Study with Hospitalized H1N1 Infected Patients
3. Second U.S.-Egypt Collaborative Clinical Study Blocked by New York State Department of Health (NYSDOH), This Time on Complications of Diabetes
4. CBI Announces the Agenda for Their West Coast Forum on Clinical Supply Chain Management
5. CryoLife Announces First Clinical Use of BioFoam(R)
6. Access Pharmaceuticals Provides Update on ProLindac(TM)Clinical Development Plan
7. Mpex Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results with Aeroquin(R) (MP-376) Treatment in Cystic Fibrosis Patients
8. Esperance Pharmaceuticals Announces Initiation of Clinical Studies of its Novel Membrane-disrupting Agent, EP-100, in Patients with Cancer
9. /C O R R E C T I O N -- Clinical Therapeutics/
10. Biovista Inc. Announces Positive Efficacy Results in a Pre-clinical Trial of its BVA-201 Repositioned Drug for Multiple Sclerosis
11. Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... After several promising treatments in ... the City of Knowledge in Panama, a 6 year-old Duchenne’s muscular dystrophy patient ... this year following FDA approval of a second application for a single patient, ...
(Date:5/25/2016)... ... May 25, 2016 , ... Thailand’s Board of Investment’s ... in San Francisco. Located at booth number 7301, representatives from the Thai Government, ... discuss the Thai biotechnology and life sciences sector. , Deputy Secretary General ...
(Date:5/25/2016)... ... May 25, 2016 , ... Scientists at the University of Athens say they ... may be hampering the research that could lead to one good one. Surviving Mesothelioma ... it now. , The team evaluated 98 mesothelioma patients who got ...
(Date:5/24/2016)... Worcester, Mass. (PRWEB) , ... May 24, 2016 ... ... including heart attacks, diabetes, and traumatic injuries, will be accelerated by research at ... skin cells into engines of wound healing and tissue regeneration. , The novel ...
Breaking Biology Technology:
(Date:3/15/2016)... JERUSALEM , March 15, 2016 ... Jerusalem , the technology-transfer company of the Hebrew University, ... developer of remote sensing technology of various human biological ... funding, raising $2.0 million from private investors. ... technology, based on the detection of electromagnetic emissions from ...
(Date:3/14/2016)... Allemagne, March 14, 2016 ... - --> - Renvoi : image disponible ... --> --> DERMALOG, ... fournit de nouveaux lecteurs d,empreintes digitales pour l,enregistrement ... DERMALOG sera utilisé pour produire des cartes d,identité ...
(Date:3/11/2016)... , March 11, 2016 ... new market research report "Image Recognition Market by Technology ... (Marketing and Advertising), by Deployment Type (On-Premises and Cloud), ... To 2022", published by MarketsandMarkets, the global market is ... to USD 29.98 Billion by 2020, at a CAGR ...
Breaking Biology News(10 mins):